| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.3 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |